StreetAlpha
13F holdings · Q3 2026

EcoR1 Capital

San Francisco, CA · files as EcoR1 Capital, LLC
Know the moment EcoR1 Capital filesYou follow EcoR1 Capital An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1587114

EcoR1 Capital reported 34 stocks worth $2B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are ZYME (29.9%), ANAB (19.5%) and CGON (6.5%). Compared with Q2 2026, the fund opened new positions in ANRO, ATTO and ADRX, added to CGON, ETON and ERAS, trimmed ORIC, BBOT and ZURA and sold out of LEGN, MBX and RLAY.

Latest filing: what EcoR1 Capital did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
9 new8 added3 trimmed6 sold outBought about $261M · sold about $125M
New 9
See all 9 →
Added 8
See all 8 →
Trimmed 3
Sold out 6
See all 6 →

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$2B+0.9% vs last quarter · $2.3B including options
Stocks held349 new · 6 sold out
Top 5 weight67.7%very concentrated
Turnover19%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
ZYME
Zymeworks Inc
$608M29.9%23MNo change8 of 8
2
ANAB
Anaptysbio Inc
$396M19.5%7.9MNo change8 of 8
3
CGON
CG Oncology Inc
$133M6.5%1.9M+378K (+25%)4 of 8
4
ETON
Eton Pharmaceuticals Inc
$127M6.3%2.5M+299K (+14%)8 of 8
5
TRAX
First Tracks Biotherapeutics
$113M5.5%3.2MNo change2 of 8
6
AKTS
Aktis Oncology Inc
$93.9M4.6%4.8MNo change3 of 8
7
CRSP
Crispr Therapeutics
$76.9M3.8%1.4MNo change8 of 8
8
ANRO
Alto Neuroscience Inc
$57M2.8%2.2MNew position1 of 8
9
LKFT
Galapagos NV
$49.4M2.4%1.7MNo change8 of 8
10
ERAS
Erasca Inc
$43.2M2.1%3M+2.6M (+794%)3 of 8
🔒 24 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
LEGN
Legend Biotech Corp
$23.1M800K
MBX
Mbx Biosciences Inc
$21.4M389K
RLAY
Relay Therapeutics Inc
$13.1M698K
PHAT
Phathom Pharmaceuticals Inc
$6.8M625K
MREO
Mereo Biopharma Group PLC
$318K1M

🔒 Free account: see all 6.

Options

valued at the underlying shares
StockTypeValueSharesChange
BMY
Bristol Myers Squibb Co
Call$218M3.5M+3,500,000
CGON
CG Oncology Inc
Call$7K100−561,400

Reported value

last 8 quarters
$2.5BQ4 '24
$1.7BQ1 '25
$1.7BQ2 '25
$2.1BQ3 '25
$2.2BQ4 '25
$2.3BQ1 '26
$2BQ2 '26
$2BQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

EcoR1 Capital 13F FAQ

What does EcoR1 Capital own?

EcoR1 Capital reported 34 stocks worth $2B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are ZYME (29.9%), ANAB (19.5%) and CGON (6.5%). The table above lists every position in the filing (the top 10 without an account).

What did EcoR1 Capital buy and sell in Q3 2026?

Compared with Q2 2026: 9 new positions, 8 added to, 3 trimmed and 6 sold out. New positions include ANRO, ATTO and ADRX. It sold all of LEGN, MBX and RLAY.

When will EcoR1 Capital file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is EcoR1 Capital's portfolio worth?

The Q3 2026 filing reports $2B in US stocks ($2.3B including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.